Eye conditions: general and other | Guidance and guideline topic | NICE

Everything NICE has produced on the topic of eye conditions: general and other. Includes any related advice.

6 new

and

0 updated

products since January 2017.

NICE Medtech innovation briefings

AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46) December 2015
Boston Keratoprosthesis Type I for corneal blindness (MIB91) January 2017
Icare rebound tonometer to measure intraocular pressure (MIB57) March 2016
LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29) April 2015
TearLab osmolarity system for diagnosing dry eye disease (MIB47) December 2015

Technology appraisal guidance

Interventional procedures guidance

Corneal endothelial transplantation (IPG304) June 2009
Corneal implants for the correction of refractive error (IPG225) July 2007
Endoscopic dacryocystorhinostomy (IPG113) February 2005
Implantation of an opaque intraocular lens for intractable double vision (IPG293) March 2009
Insertion of a subretinal prosthesis system for retinitis pigmentosa (IPG537) December 2015
Insertion of an epiretinal prosthesis for retinitis pigmentosa (IPG519) June 2015
Retrobulbar irradiation for thyroid eye disease (IPG148) December 2005
Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) (IPG299) May 2009

NICE Evidence summaries

Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76) June 2016

In development

Adults with a lifelong or very severe hearing or visual impairment: health and social care support (GID-NG10042) TBC NICE guidelines
Aflibercept for treating myopic choroidal neovascularisation [ID952] (GID-TA10132) January 2018 Technology appraisal guidance
Eculizumab for treating refractory myasthenia gravis [ID1064] (GID-TA10176) May 2018 Technology appraisal guidance
Holoclar for treating limbal stem cell deficiency after eye burns [ID899] (GID-TA10044) August 2017 Technology appraisal guidance
Uveitis (non-infectious) - adalimumab and dexamethasone [ID763] (GID-TA10007) July 2017 Technology appraisal guidance